Drug Type Small molecule drug |
Synonyms 5-Fluoro-2-methyl-1-((Z)-p-(methylsulfonyl)benzylidene)indene-3-acetic acid, Aptosyn, cis-5-Fluoro-2-methyl-1-(p-methylsulfonylbenzylidenyl)indene-3-acetic acid + [5] |
Target |
Mechanism PDE5A inhibitors(Phosphodiesterase 5A inhibitors), cGMP-PDE inhibitors(3',5'-cyclic phosphodiesterase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC20H17FO4S |
InChIKeyMVGSNCBCUWPVDA-MFOYZWKCSA-N |
CAS Registry59973-80-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 3 | US | 01 Apr 2001 | |
Adenomatous Polyposis Coli | Phase 3 | US | - | - |
Adenomatous Polyposis Coli | Phase 3 | IL | - | - |
Adenomatous Polyposis Coli | Phase 3 | SE | - | - |
Adenomatous Polyposis Coli | Phase 3 | GB | - | - |
Adenomatous Polyposis Coli | Phase 3 | - | - | |
Adenomatous Polyposis Coli | Phase 3 | - | - | |
Breast Cancer | Phase 3 | US | - | - |
Prostatic Cancer | Phase 3 | US | - | - |
Prostatic Cancer | Phase 3 | CA | - | - |
Phase 2 | 32 | luteinizing hormone-releasing hormone (LHRH) agonist+Exisulind | ntlukvgiww(hcwpojwvni) = tphjvokmjq awodrtbmac (uylkyqjhcj, lbnnojmftr - xdvlewttsn) View more | - | 14 May 2018 | ||
Phase 2 | 19 | dkttzfpyol(nrfbpeeily) = 53% mkxteqzkqn (cjlwjjzosi ) View more | - | 20 Feb 2013 | |||
Phase 2 | 57 | ufndtgpeja(bzbmujheut) = lkygrvihoz rxlvryohlz (awlddomuts ) View more | - | 01 Sep 2006 | |||
Phase 2 | 58 | uvfluexqmw(rbziebjded) = cikguckvzy qingoaheuu (heblinmxjz ) View more | - | 15 Jul 2004 | |||
Phase 1/2 | 33 | tgtcbhjafb(jmbbfoepha) = fmrjaqtrnv bnkostcfuz (aeaqbdabdx ) | - | 15 Jul 2004 | |||
Phase 1/2 | 30 | srwiedjjdg(lwgvoqbeep) = lcurdpgrzi idwbatzcrx (gcgvdmzzko ) View more | - | 15 Jul 2004 |